Tillman Gerngross (Photo by Craig F. Walker/The Boston Globe via Getty Images)
February 15, 2023 08:35 AM EST
Startups
Deals

Till­man Gern­gross’ Am­ag­ma Ther­a­peu­tics qui­et­ly ships an­ti­bod­ies to an­oth­er biotech

Kyle LaHucik

Senior Reporter

A biotech from an­ti­body leg­end Till­man Gern­gross and stem cell leader Leonard Zon has fold­ed in­to an­oth­er com­pa­ny, merg­ing with an undis­closed biotech.

The duo …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times